GRAIL - Meet A Vendor
Shortlister hosted Scott Osler, Sr. Director of Employer Partnerships at GRAIL to share how the Galleri Multi-Cancer Early Detection Test available to employees is a potentially life-changing benefit.
GRAIL is a healthcare company formed in 2016 from a world-class team of leaders, scientists, clinicians, engineers, and other experts, with the purpose to detect cancer early, when it can be cured.
The company headquarter is in Silicon Valley, at the heart of the intersection of the life sciences and technology industries and supported by leading global investors and pharmaceutical, technology, and healthcare companies.
MEETING THE NEEDS THAT MAY CHANGE A LIFE
The earlier that cancer can be found, the higher the chance of successful treatment and survival.
The statistics just confirms it:
Cancer is one of the largest healthcare spend categories for employers. Employer cancer care costs are growing at 2x the rate of other healthcare expenses. Additionally, the treatment of late-stage cancer can cost 2 times more than early-stage cancer. Diagnosed at earlier stages leads to fewer disability claims and less frequent early departures from the workforce.
THE MULTI-CANCER EARLY DETECTION TEST GALLERI™
GRAIL is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges with the Galleri™ multi-cancer early detection blood test. It is a ground-breaking and potentially life-saving advancement in cancer detection.
The compelling results supported by large clinical studies show that with Galleri™ Test, a simple blood draw can lead to unique results:
EMPLOYEE BENEFITS MARKET RESEARCH
The results showed the following:
EMPLOYER PARTNERSHIP MODEL
GRAIL’s commitment is to enable a seamless and positive employee experience. They do that with a comprehensive and consumer-oriented test experience which consists of four steps:
Currently, there are no effective early detection tests for the majority of cancer types, and many deadly cancers are often detected too late. Galleri has demonstrated the ability to detect more than 50 cancers and predict, with high accuracy, where the cancer signal originated in the body, all of this from a single blood draw.
Log in to access the full Meet A Vendor Presentation!
Not a subscriber? Let’s get in touch!